BioSpace News Archive

Next Gen Diagnostics announces that Dr. Linoj Samuel, Division Head of the Clinical Microbiology Laboratory for Henry Ford Health in Detroit Michigan, has joined NGD’s Scientific Advisory Board.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on June 3, 2024, Anika granted: non-statutory stock options covering 96,525 shares of common stock at a per share exercise price of $29.35.

Seres Therapeutics, Inc. announced that on June 5, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units covering 2,063 shares of its common stock.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced the results of its Annual Meeting of shareholders.

Gossamer Bio, Inc. announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective June 5, 2024, to one new non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 170,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar’s common stock on June 3, 2024, the grant date of the award.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024.

Taysha Gene Therapies, Inc. announced that, on June 3, 2024, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company’s common stock in connection with their employment.